netFormulary Harrogate & Rural District Formulary NHS
Harrogate & District NHS Foundation Trust
Harrogate & Rural District Clinical Commissioning Group
 
 
 Search
 Formulary Chapter 1: Gastro-intestinal system - Full Chapter
Chapter Links...
 Details...
01.06.07  Expand sub section  5HT4 receptor agonists and guanylate cyclase-C receptor agonists
Linaclotide  (Constella)
(290mcg capsules)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Amber
Approved for one patient only - September 2014 
Link  NICE ESNM16: Irritable bowel syndrome with constipation in adults: linaclotide
   
Lubiprostone (Amitiza )
(24mcg capsules)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
Approved by the Area Prescribing Committee September 2014 in line with NICE TA318 
Link  NICE TA318 Lubiprostone for treating chronic idiopathic constipation
   
Prucalopride (Resolor)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Amber

Tablets 1mg

Initiation on the advice of a specialist only.
For chronic constipation in adults when all other laxatives have been ineffective after 6 months.

 
Link  NICE TA211: Prucalopride for constipation in women
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber

Medicines which are suitable to be prescribed in primary care only after specialist recommendation. Ongoing prescribing by primary care includes titration of dose and assessment of efficacy. There is no need for ongoing monitoring other than for general adverse effects as listed in the BNF & SPC.  

Amber Shared Care

Medicines which are suitable to be prescribed in primary care only after specialist recommendation only under a shared care protocol once the patient has been stabilised. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must be approved by the Harrogate & Rurual District Area Prescribing Committee (HaRD APC).   

Black

Medicines which the Harrogate & Rural District Area Prescribing Committee (HaRD APC) has reviewed and does not recommend for use at present based on a review of clinical and/or cost effectiveness data.   

Green

Medicines suitable for routine use and can be prescribed within primary care within their licensed indication in accordance with nationally recognised formularies e.g. BNF, BNF for Children, Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing.  

Grey

Medicines which the Harrogate & Rural District Area Prescribing Committee (HaRD APC) have not yet reviewed.   

Red

Medicines for hospital use only. The responsibility for initiation and monitoring treatment should rest with an appropriate hospital clinician. The drug should be supplied by the hospital for the duration of the treatment course. Primary care prescriber initiation or continuation of treatemnt is not recommended.  

netFormulary